12:25 PM EST - Psyence Group Inc : Announced that it is exploring capital market opportunities to access a broader pool of United Kingdom and European investors. This includes a potential dual listing in the UK. Psyence has a worldwide investor base, including shareholders in the UK and Europe, and is initiating a clinical trial in the UK using its natural psilocybin in the field of palliative care with oncology patients. Psyence Group Inc
shares C.PSYG are trading unchanged at $0.16.
